MedTrace Logo

Dampening the Reproductive Axis With Continuous Kisspeptin

NCT05971849 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-11-05

No results posted yet for this study

Summary

The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).

Conditions

  • Reproductive Disorder
  • PCOS
  • Polycystic Ovary Syndrome

Interventions

DRUG

kisspeptin 112-121

IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin

Sponsors & Collaborators

  • Stephanie B. Seminara, MD

    lead OTHER

Principal Investigators

  • Stephanie B Seminara, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-06
Primary Completion
2024-04-27
Completion
2024-04-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05971849 on ClinicalTrials.gov